Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metis TechBio CoFRA:RO9 +7.99%17 Days Payable is 636.15 as of Dec. 2025, which is 83% below its 10-year median of 3,808.50. GuruFocus rates FRA:RO9 with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 704 Biotechnology companies, Metis TechBio Co ranks better than 91.05% on this metric.
The historical rank and industry rank for Metis TechBio Co's Days Payable or its related term are showing as below:
FRA:RO9'
s Days Payable Range Over the Past 10 Years
Min: 932.42 Med: 3808.5 Max: 14406.76
Current: 2497.5
During the past 4 years, Metis TechBio Co's highest Days Payable was 14406.76. The lowest was 932.42. And the median was 3808.50.
FRA:RO9's Days Payable is ranked better than 91.05% of 704
companies
in the Biotechnology industry
Industry Median: 112.715
vs FRA:RO9: 2497.50
Metis TechBio Co's Days Payable
increased
from Dec. 2022 (0.00) to Dec. 2025 (636.15).
It may suggest that Metis TechBio Codelayed paying its suppliers.
The historical data trend for Metis TechBio Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co Days Payable Chart
Metis TechBio Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Days Payable
14,400.91
948.09
5,525.93
2,114.48
Metis TechBio Co Quarterly Data
Dec22
Dec23
Dec24
Sep25
Dec25
Days Payable
0.00
0.00
2,700.17
0.00
636.15
FRA:RO9 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Metis TechBio Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metis TechBio Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metis TechBio Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Metis TechBio Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Metis TechBio Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co (FRA:RO9) has a Days Payable of 636.15 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Metis TechBio Co and its competitors. This is 83% below median its historical median of 3,808.50. Over the past decade, Metis TechBio Co's Days Payable has ranged from 932.42 to 14,406.76. According to the industry distribution chart, Metis TechBio Co ranks #63 out of 704 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Metis TechBio Co's Days Payable too high?
Metis TechBio Co's current Days Payable of 636.15 is 83% below median its 10-year median of 3,808.50. Over the past 10 years, this metric has ranged from a low of 932.42 to a high of 14,406.76. The Biotechnology industry median Days Payable is 112.72. Metis TechBio Co's value of 636.15 is 464.4% above this industry median. Based on the distribution chart, Metis TechBio Co ranks #63 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Metis TechBio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Metis TechBio Co ranks #63 out of 704 companies for Days Payable. This places Metis TechBio Co in the top 9% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.72. Metis TechBio Co's value of 636.15 is 464.4% above this benchmark. Historically, Metis TechBio Co's own Days Payable has ranged from 932.42 to 14,406.76 over the past decade. While the company's 10-year median is 3,808.50 vs. the industry median of 112.72, Metis TechBio Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metis TechBio Co's current Days Payable of 636.15 is 464.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Metis TechBio Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metis TechBio Co's current Days Payable is 636.15, which is 83% below median its own 10-year median of 3,808.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (FRA:RO9) has a current Days Payable of 636.15. The current Days Payable is 636.15, which is 83% below median its 10-year median of 3,808.50 and 464.4% above the Biotechnology industry median of 112.72. Metis TechBio Co's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Metis TechBio Co (FRA:RO9), the current Days Payable is 636.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
17GF Score
Get the complete analysis for FRA:RO9
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RO9 has been successfully added to your 
